Lenvatinib
- PDF / 169,119 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 95 Downloads / 173 Views
1 S
Diarrhoea, hand-foot skin reaction and hepatic encephalopathy: case report In a retrospective study of 23 patients treated with lenvatinib between April–September 2018, one patient [age and sex not stated] was described, who developed hand-foot skin reaction, diarrhoea and hepatic encephalopathy during treatment with lenvatinib for advanced hepatocellular carcinoma (HCC). The patient, who was diagnosed with HCC, started receiving oral lenvatinib daily [dose not stated]. However, the patient subsequently developed hand-foot skin reaction, diarrhoea and hepatic encephalopathy secondary to the treatment with lenvatinib [durations of treatment to reactions onset not stated]. The treatment with lenvatinib was not discontinued [outcomes not stated]. Ohya K, et al. Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy. Scientific Reports 9: No. 803517604 1, 20 Aug 2019. Available from: URL: http://doi.org/10.1038/s41598-019-48045-z
0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 28 Nov 2020 No. 1832
Data Loading...
